ID

34743

Description

Effects of Pramlintide on Endogenous Production of Very-low-density-lipoprotein (VLDL)-Triglyceride and Glucose in the Post Prandial State in T2DM; ODM derived from: https://clinicaltrials.gov/show/NCT00732147

Link

https://clinicaltrials.gov/show/NCT00732147

Keywords

  1. 1/25/19 1/25/19 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

January 25, 2019

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Type 2 Diabetes NCT00732147

Eligibility Type 2 Diabetes NCT00732147

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
type 2 dm study participants will be c-peptide positive (levels > 0.3 nmol/l)
Description

Diabetes Mellitus, Non-Insulin-Dependent | C-Peptide Positive | Insulin C-peptide measurement

Data type

boolean

Alias
UMLS CUI [1]
C0011860
UMLS CUI [2,1]
C0006558
UMLS CUI [2,2]
C1514241
UMLS CUI [3]
C0202100
receiving insulin, metformin and/or sulfonylurea/glitinide.
Description

Insulin | Metformin | Sulfonylurea | Meglitinide

Data type

boolean

Alias
UMLS CUI [1]
C0021641
UMLS CUI [2]
C0025598
UMLS CUI [3]
C0038766
UMLS CUI [4]
C0065880
maintained on stable anti-hypertensive medication.
Description

Antihypertensive Agents Stable

Data type

boolean

Alias
UMLS CUI [1,1]
C0003364
UMLS CUI [1,2]
C0205360
bmi < 52 kg/m2.
Description

Body mass index

Data type

boolean

Alias
UMLS CUI [1]
C1305855
t2dm for at least 3 months with hba1c under 10%.
Description

Non-Insulin-Dependent Diabetes Mellitus Disease length | Hemoglobin A1c measurement

Data type

boolean

Alias
UMLS CUI [1,1]
C0011860
UMLS CUI [1,2]
C0872146
UMLS CUI [2]
C0474680
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
receiving tzds, exenatide, sitagliptin or pramlintide therapy.
Description

Thiazolidinediones | exenatide | sitagliptin | Pramlintide

Data type

boolean

Alias
UMLS CUI [1]
C1257987
UMLS CUI [2]
C0167117
UMLS CUI [3]
C1565750
UMLS CUI [4]
C0537551
receiving medications known to impair gastric emptying, intestinal motility, glucagon release or corticosteroids.
Description

Pharmaceutical Preparations Impairing Gastric Emptying | Pharmaceutical Preparations Impairing Intestinal Motility | Pharmaceutical Preparations Impairing Glucagon secretion | Adrenal Cortex Hormones

Data type

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0221099
UMLS CUI [1,3]
C0017127
UMLS CUI [2,1]
C0013227
UMLS CUI [2,2]
C0221099
UMLS CUI [2,3]
C0021838
UMLS CUI [3,1]
C0013227
UMLS CUI [3,2]
C0221099
UMLS CUI [3,3]
C2610739
UMLS CUI [4]
C0001617
triglyceride levels > 400 mg/dl.
Description

Triglycerides measurement

Data type

boolean

Alias
UMLS CUI [1]
C0202236
bmi > 52 kg/m2.
Description

Body mass index

Data type

boolean

Alias
UMLS CUI [1]
C1305855

Similar models

Eligibility Type 2 Diabetes NCT00732147

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Diabetes Mellitus, Non-Insulin-Dependent | C-Peptide Positive | Insulin C-peptide measurement
Item
type 2 dm study participants will be c-peptide positive (levels > 0.3 nmol/l)
boolean
C0011860 (UMLS CUI [1])
C0006558 (UMLS CUI [2,1])
C1514241 (UMLS CUI [2,2])
C0202100 (UMLS CUI [3])
Insulin | Metformin | Sulfonylurea | Meglitinide
Item
receiving insulin, metformin and/or sulfonylurea/glitinide.
boolean
C0021641 (UMLS CUI [1])
C0025598 (UMLS CUI [2])
C0038766 (UMLS CUI [3])
C0065880 (UMLS CUI [4])
Antihypertensive Agents Stable
Item
maintained on stable anti-hypertensive medication.
boolean
C0003364 (UMLS CUI [1,1])
C0205360 (UMLS CUI [1,2])
Body mass index
Item
bmi < 52 kg/m2.
boolean
C1305855 (UMLS CUI [1])
Non-Insulin-Dependent Diabetes Mellitus Disease length | Hemoglobin A1c measurement
Item
t2dm for at least 3 months with hba1c under 10%.
boolean
C0011860 (UMLS CUI [1,1])
C0872146 (UMLS CUI [1,2])
C0474680 (UMLS CUI [2])
Item Group
C0680251 (UMLS CUI)
Thiazolidinediones | exenatide | sitagliptin | Pramlintide
Item
receiving tzds, exenatide, sitagliptin or pramlintide therapy.
boolean
C1257987 (UMLS CUI [1])
C0167117 (UMLS CUI [2])
C1565750 (UMLS CUI [3])
C0537551 (UMLS CUI [4])
Pharmaceutical Preparations Impairing Gastric Emptying | Pharmaceutical Preparations Impairing Intestinal Motility | Pharmaceutical Preparations Impairing Glucagon secretion | Adrenal Cortex Hormones
Item
receiving medications known to impair gastric emptying, intestinal motility, glucagon release or corticosteroids.
boolean
C0013227 (UMLS CUI [1,1])
C0221099 (UMLS CUI [1,2])
C0017127 (UMLS CUI [1,3])
C0013227 (UMLS CUI [2,1])
C0221099 (UMLS CUI [2,2])
C0021838 (UMLS CUI [2,3])
C0013227 (UMLS CUI [3,1])
C0221099 (UMLS CUI [3,2])
C2610739 (UMLS CUI [3,3])
C0001617 (UMLS CUI [4])
Triglycerides measurement
Item
triglyceride levels > 400 mg/dl.
boolean
C0202236 (UMLS CUI [1])
Body mass index
Item
bmi > 52 kg/m2.
boolean
C1305855 (UMLS CUI [1])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial